Lynx1 Capital Management’s ProQR Therapeutics PRQR Stock Holding History
Bought
Maintained
Sold
Other funds holding PRQR
6CM
KCM
Lynx1 Capital Management's PRQR Position: Q3 2026 in Review
Lynx1 Capital Management increased its ProQR Therapeutics (PRQR) stake by 200% in Q3 2026, buying an estimated $1.97M and bringing the position to 1,562,093 shares worth $2.59M. The position accounts for 0.4% of the portfolio, ranked #10.
Lynx1 Capital Management first reported a position in PRQR in Q4 2025 and has held it in 4 quarters since. 73 funds tracked by Wall St. Rank hold PRQR as of Q3 2026.
- Lynx1 Capital Management held 1,562,093 shares of ProQR Therapeutics worth $2.59M as of Q3 2026.
- Lynx1 Capital Management bought 1,040,680 ProQR Therapeutics shares in Q3 2026, an estimated $1.97M.
- ProQR Therapeutics made up 0.4% of Lynx1 Capital Management's portfolio in Q3 2026, its #10 holding.
- Lynx1 Capital Management first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 73 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2026.
Based on Lynx1 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.